Marijuana Stocks Newsletter – August 30, 2018

MJStocks Thursday Update- 8/30/2018!

GTEC Holdings Ltd. (GTEC.V) (GGTTF) Signs LOI with Invictus MD To Receive Strategic Investment And Expand National Distribution
GTEC Holdings Ltd. (“GTEC” or the “Company”) (GTEC.V) (GGTTF) is pleased to announce that it has entered into a binding Letter of Intent with Invictus MD Strategies Corp. (“Invictus”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) to provide GTEC with a non-revolving unsecured convertible loan (the “Loan Facility“) in an amount up to $2,000,000 , and an interest rate of prime plus 5%. Upon mutual agreement of both parties prior to the Maturity Date, Invictus may increase the amount of the Loan Facility up to $6,000,000 .
Click Here For Full Release

Why Is GT Biopharma (GTBP) Seeing So Much Activity Right Now?
It’s clear that companies like Gilead or Merck don’t have any plans on slowing down the M&A trend anytime soon. Gilead’s CEO has even said that the company is “quite interested in things that would augment cellular therapy.”

This week, GT Biopharma (GTBP) has been trending after it made a major announcement. The company has initiated a combination trial of its OXS-1550 with a multi-billion dollar oncology drug, owned by a Major Pharmaceutical Company. What is the multi-billion dollar oncology drug & why is the market starting to pay closer attention to GT Biopharma (GTBP)?
Click Here To Read More

A Guide for Investing in The Cannabis Industry
The industry on cannabis has remained incredibly lucrative for some time now and given the changing legislation around the world and the shifting public sentiment, it seems as though this is only the beginning. There are many strategies when it comes to investing within the cannabis industry, but there are also a few basics that any investor should know before putting any money in.
Click Here For More

Disclaimer: Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GTEC Holdings Inc., Midam is being paid $63,333 per month from the company for a total of 12 months and has received ZERO shares of GTEC Holdings Inc. for a duration of beginning July 10, 2018 and ending July 10, 2019. We may buy or sell additional shares of (GTEC) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.